We Offer Worldwide Shipping
Login Wishlist

Pseudoginsenoside RT1

$496

  • Brand : BIOFRON

  • Catalogue Number : BD-P0054

  • Specification : 98.0%(HPLC)

  • CAS number : 98474-74-9

  • Formula : C47H74O18

  • Molecular Weight : 927.08

  • PUBCHEM ID : 21633069

  • Volume : 50mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0054

Analysis Method

HPLC,NMR,MS

Specification

98.0%(HPLC)

Storage

2-8°C

Molecular Weight

927.08

Appearance

Powder

Botanical Source

Structure Type

Triterpenoids

Category

SMILES

CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)OC6C(C(C(C(O6)C(=O)O)O)O)OC7C(C(C(CO7)O)O)O)C)C)C2C1)C)C(=O)OC8C(C(C(C(O8)CO)O)O)O)C

Synonyms

(2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,12aS,14aR,14bR)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4-dihydroxy-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid

IUPAC Name

(2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,12aS,14aR,14bR)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4-dihydroxy-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid

Applications

Biological Activity of Crude Extract and Saponin Pseudoginsenoside-RT1 Derived from the Fruit of Randia siamensis PUMID/DOI:无 Pharmaceutical Biology, 2008 ,37 (1) :42-45. Ursolic acid (1), pseudoginsenoside-RP 1 (2), and Pseudoginsenoside RT1 (3) were isolated from the fruit of Randia siamensis. 13 C NMR spectroscopy was particularly useful in confirming the structures of these components. Studies with rats showed that saponin 3 caused a decrease in blood pressure, an increase in heart rate and an increase in spontaneous contractility of the uterus. Also, a crude ethanol extract of the fruit of R. siamensis exhibited acute ichthyotoxic activity.

Density

1.42±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

Boiling Point

Melting Point

InChl

InChI=1S/C47H74O18/c1-42(2)14-16-47(41(59)65-39-34(56)30(52)29(51)24(19-48)61-39)17-15-45(6)21(22(47)18-42)8-9-26-44(5)12-11-27(43(3,4)25(44)10-13-46(26,45)7)62-40-36(32(54)31(53)35(63-40)37(57)58)64-38-33(55)28(50)23(49)20-60-38/h8,22-36,38-40,48-56H,9-20H2,1-7H3,(H,57,58)/t22-,23+,24+,25-,26+,27-,28-,29+,30-,31-,32-,33+,34+,35-,36+,38-,39-,40+,44-,45+,46+,47-/m0/s1

InChl Key

YTPBUIWNJRGZFW-HONMPOSFSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:98474-74-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

29652263

Abstract

Specific radiation damage can be used to determine phases de novo from macromolecular crystals. This method is known as radiation-damage-induced phasing (RIP). One limitation of the method is that the dose of individual data sets must be minimized, which in turn leads to data sets with low multiplicity. A solution to this problem is to use data from multiple crystals. However, the resulting signal can be degraded by a lack of isomorphism between crystals. Here, it is shown that serial synchrotron crystallography in combination with selective merging of data sets can be used to determine high-quality phases for insulin and thaumatin, and that the increased multiplicity can greatly enhance the success rate of the experiment.

KEYWORDS

synchrotron serial crystallography, radiation-damage-induced phasing, experimental phasing, radiation damage, genetic algorithms

Title

X-ray and UV radiation-damage-induced phasing using synchrotron serial crystallography

Author

Nicolas Foos,a Carolin Seuring,b,c Robin Schubert,c,d,e Anja Burkhardt,f Olof Svensson,a Alke Meents,b Henry N. Chapman,b,c,g and Max H. Nanaoa,*

Publish date

2018 Apr 1

PMID

28715610

Abstract

Background
Drugs can prevent postoperative nausea and vomiting, but their relative efficacies and side effects have not been compared within one systematic review.

Objectives
The objective of this review was to assess the prevention of postoperative nausea and vomiting by drugs and the development of any side effects.

Search methods
We searched The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 2, 2004), MEDLINE (January 1966 to May 2004), EMBASE (January 1985 to May 2004), CINAHL (1982 to May 2004), AMED (1985 to May 2004), SIGLE (to May 2004), ISI WOS (to May 2004), LILAC (to May 2004) and INGENTA bibliographies.

Selection criteria
We included randomized controlled trials that compared a drug with placebo or another drug, or compared doses or timing of administration, that reported postoperative nausea or vomiting as an outcome.

Data collection and analysis
Two authors independently assessed trial quality and extracted outcome data.

Main results
We included 737 studies involving 103,237 people. Compared to placebo, eight drugs prevented postoperative nausea and vomiting: droperidol, metoclopramide, ondansetron, tropisetron, dolasetron, dexamethasone, cyclizine and granisetron. Publication bias makes evidence for differences among these drugs unreliable. The relative risks (RR) versus placebo varied between 0.60 and 0.80, depending upon the drug and outcome. Evidence for side effects was sparse: droperidol was sedative (RR 1.32) and headache was more common after ondansetron (RR 1.16).

Authors’ conclusions
Either nausea or vomiting is reported to affect, at most, 80 out of 100 people after surgery. If all 100 of these people are given one of the listed drugs, about 28 would benefit and 72 would not. Nausea and vomiting are usually less common and, therefore, drugs are less useful. For 100 people, of whom 30 would vomit or feel sick after surgery if given placebo, 10 people would benefit from a drug and 90 would not. Between one to five patients out of every 100 people may experience a mild side effect, such as sedation or headache, when given an antiemetic drug. Collaborative research should focus on determining whether antiemetic drugs cause more severe, probably rare, side effects. Further comparison of the antiemetic effect of one drug versus another is not a research priority.

KEYWORDS

Humans, Antiemetics, Antiemetics/therapeutic use, Postoperative Nausea and Vomiting, Postoperative Nausea and Vomiting/prevention & control, Randomized Controlled Trials as Topic

Title

Drugs for preventing postoperative nausea and vomiting

Author

John Carlislecorresponding author and Carl A Stevenson

Publish date

2017 Jul;

PMID

29159234

Abstract

This data article contains complementary tables related to the research article entitled, ‘Effects of repetitive transcranial magnetic stimulation on ER stress-related genes and glutamate, γ-aminobutyric acid, and glycine transporter genes in mouse brain’ (Ikeda et al. (2017) [1]), which showed that rTMS modulates glutamate, GABA and glycine transporters and regulates ER stress-related genes. Here we provide accompanying data collected using Affymetrix GeneChip microarrays to identify changes in gene expression in mouse cerebrum treated with rTMS for 30 days (Tables 1-10).

Title

Gene expression microarray data from mouse cerebrum treated with rTMS for 30 days

Author

Tetsurou Ikeda,a,b,1,* Satoru Kobayashi,c and Chikao Morimotob

Publish date

2017 Dec